← Leaderboards
Benjamin Z Leder
Massachusetts General Hospital
$7,400,681
Attributed
$8,520,045
Total exposure
18
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $919.2K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,520,045 · 18
By mechanism
R01$4,017,447 · 2
R21$1,832,406 · 3
K24$926,268 · 1
K23$648,946 · 1
M01$598,836 · 9
R34$452,794 · 1
Top collaborators
- Marie Demay5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Marc Nathan Wein$4,989,017
- Roland E Baron$29,888,429
- Pouneh Khadejeh Fazeli$3,583,785
- Marie Demay$19,218,520
- Joel S Finkelstein$18,947,740
Others in their field
Top investigators on “Osteoporosis”
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Steven R Cummings · University Of California San Francisco$56,375,786
- Richard A Gibbs · Baylor College Of Medicine$49,965,365
- Peter J. Snyder · University Of Pennsylvania$36,531,878
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$32,610,184
- Eric S. Orwoll · Oregon Health And Science University$28,146,073
Research focus
OsteoporosisBone DensityOsteogenesisWomanPropertyBone MetabolismClinical TrialsAffectHigh RiskPharmaceutical PreparationsAmericanBone StrengthOsteoporosis With Pathological FracturePostmenopauseSkeletalPublic HealthRandomizedBoneBone ResorptionOsteoporoticBaseOsteoblastsFracture RiskHip Region Structure
Grant awards (41)
Combined Anabolic Therapy in Postmenopausal Osteoporosis$587,840
R21 · FY2024 · AR · contact PI
Limited-duration anabolic therapy in postmenopausal osteoporosis$181,120
R21 · FY2023 · AR · contact PI
Limited-duration anabolic therapy in postmenopausal osteoporosis$80,000
R21 · FY2023 · AR · contact PI
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration$509,054
R01 · FY2022 · AR · contact PI
Limited-duration anabolic therapy in postmenopausal osteoporosis$179,309
R21 · FY2022 · AR · contact PI
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration$567,473
R01 · FY2021 · AR · contact PI
Limited-duration anabolic therapy in postmenopausal osteoporosis$214,400
R21 · FY2021 · AR · contact PI
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration$68,659
R01 · FY2021 · AR · contact PI
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration$574,528
R01 · FY2020 · AR · contact PI
Mechanisms Underlying the Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration$519,014
R01 · FY2019 · AR · contact PI
Combination Osteoporosis Therapy and Fracture Reduction$217,544
R34 · FY2019 · AR · contact PI
Novel combination therapies in the treatment of osteoporosis$182,670
K24 · FY2019 · AR · contact PI
Combination Osteoporosis Therapy and Fracture Reduction$235,250
R34 · FY2018 · AR · contact PI
Consolidating Skeletal Benefits after Short-Term Combination Osteoporosis Therapy; The DATA-EX Study$218,535
R21 · FY2018 · AR · contact PI
Novel combination therapies in the treatment of osteoporosis$182,670
K24 · FY2018 · AR · contact PI
Novel combination therapies in the treatment of osteoporosis$186,976
K24 · FY2017 · AR · contact PI
Consolidating Skeletal Benefits after Short-Term Combination Osteoporosis Therapy; The DATA-EX Study$185,601
R21 · FY2017 · AR · contact PI
Novel combination therapies in the treatment of osteoporosis$186,976
K24 · FY2016 · AR · contact PI
Consolidating Skeletal Benefits after Short-Term Combination Osteoporosis Therapy; The DATA-EX Study$185,601
R21 · FY2016 · AR · contact PI
Novel combination therapies in the treatment of osteoporosis$186,976
K24 · FY2015 · AR · contact PI
Aromatase inhibition in elderly hypogonadal men$345,552
R01 · FY2009 · AG · contact PI
Aromatase inhibition in elderly hypogonadal men$345,552
R01 · FY2008 · AG · contact PI
CLINICAL TRIAL: ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN$11,980
M01 · FY2008 · RR · contact PI
Aromatase inhibition in elderly hypogonadal men$352,604
R01 · FY2007 · AG · contact PI
ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN$108,017
M01 · FY2007 · RR · contact PI
Aromatase inhibition in elderly hypogonadal men$363,136
R01 · FY2006 · AG · contact PI
ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN$140,049
M01 · FY2006 · RR · contact PI
EFFECTS OF ANDROGENS AND ESTROGENS ON SKELETAL SENSITIVITY TO PTH$27,928
M01 · FY2006 · RR · contact PI
DOES INCREASED EDUCATION OF SIDE EFFECTS/INCREASE SUBJ'S REPORTING SIDE EFFECTS$1,232
M01 · FY2006 · RR · contact PI
Aromatase inhibition in elderly hypogonadal men$371,875
R01 · FY2005 · AG
EFFECTS OF ANDROGENS AND ESTROGENS ON SKELETAL SENSITIVITY TO PTH$259,147
M01 · FY2005 · RR
DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE$129,951
K23 · FY2005 · RR
ANASTROZOLE ADMINISTRATION IN ELDERLY HYPOGONADAL MEN$17,213
M01 · FY2005 · RR
DOES INCREASED EDUCATION OF SIDE EFFECTS/INCREASE SUBJ'S REPORTING SIDE EFFECTS$10,041
M01 · FY2005 · RR
DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE$129,951
K23 · FY2004 · RR
EFFECTS OF ANDROGENS AND ESTROGENS ON SKELETAL SENSITIVITY TO PTH$22,122
M01 · FY2004 · RR
ANASTROZOLE ADMIN ON GONADAL STEROID LEVELS IN ELDERLY MEN W/ MILD HYPOGONADISM$1,107
M01 · FY2004 · RR
DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE$129,951
K23 · FY2003 · RR
DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE$129,142
K23 · FY2002 · RR
DIFFERENTIAL EFFECTS OF GONADAL STEROIDS ON BONE$129,951
K23 · FY2001 · RR
DIFFERENTIAL EFFECTS OF ANDROGENS AND ESTROGENS ON BONE$43,348
F32 · FY2000 · AR